Loading presentation...

Present Remotely

Send the link below via email or IM


Present to your audience

Start remote presentation

  • Invited audience members will follow you as you navigate and present
  • People invited to a presentation do not need a Prezi account
  • This link expires 10 minutes after you close the presentation
  • A maximum of 30 users can follow your presentation
  • Learn more about this feature in our knowledge base article

Do you really want to delete this prezi?

Neither you, nor the coeditors you shared it with will be able to recover it again.


Airlukast Ranbaxy

No description

nethiana yagi

on 4 April 2013

Comments (0)

Please log in to add your comment.

Report abuse

Transcript of Airlukast Ranbaxy

Symptoms What is Asthma? Triggers - Chronic inflammation of the bronchial tubes
that causes swelling and narrowing of the
airways which results in difficulty in
breathing. Pathophysiology Normal airway :
-No muscle thickening
-Normal airway lining
-Thin tissues Asthma Airway:
-Airway lining swollen and red
-Muscle Tightening
-Excess mucus
-Alveoli filled with trapped air Chest tightness Chronic cough Wheezing shortness of breath Treatment Acute Chronic 1. Short acting B2
- Eg : Sulbatamol
Terbutaline 1. Long acting B2
-Eg : Formeterol &

2. Corticosteroids
-Eg : Beclomethasone

3. Anti- Cholinergics
- Eg : Ipratropium

4. Leukotriene-receptor
- Eg : Montelukast
(Airlukast) What is Allergic Rhinitis? - Allergic inflammation of the nasal airways.

- Occurs when an allergen (pollen, dust or animal hair)
is inhaled by an individual with a sensitized immune
system. Treatment - Intranasal Corticosteroids

- Antihistamines

- Decongestants

- Leukotriene receptor
Eg : Montelukast
(Airlukast) The cysteinyl leukotrienes (LTC4, LTD4, LTE4) are products of arachidonic acid metabolism and are released from various cells, including mast cells and eosinophils.

These eicosanoids bind to cysteinyl leukotriene (CysLT) receptors.

The CysLT type-1 (CysLT1) receptor is found in the human airway and on other pro-inflammatory cells

Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity.

Montelukast causes inhibition of airway cysteinyl leukotriene receptors as demonstrated by the ability to inhibit bronchoconstriction due to inhaled LTD4 in asthmatics.

In allergic rhinitis, CysL Ts are released from the nasal mucosa after allergen exposure during both early-and late-phase reactions and are associated with symptoms of allergic rhinitis. Mode of Action contain montelukast sodium, which is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT1 receptor. Airlukast... Pharmacology Montelukast is rapidly absorbed following oral administration.

For the 10 mg film-coated tablet, the mean peak plasma concentration (Cmax) is achieved 3 hours (Tmax) after administration in adults in the fasted state.

The mean oral bioavailability is 64%.

Montelukast is more than 99% bound to plasma proteins.

The mean plasma half-life of montelukast ranged from 2.7 to 5.5 hours in healthy young adults. Indications Prophylaxis and chronic treatment of asthma (patients ≥ 2 years of age)

For the relief of day-time and night-time symptoms of seasonal allergic rhinitis
(patients ≥ 2 years of age) Dose and Method
of Administration Asthma :
OD in evening AR :
individualized to
suit patient needs Asthma & AR:
OD in evening Dosage : - 4mg chewable tablet
- OD dosage
- Paediatric patients
2-5 years of age - 5mg chewable tablet
- OD dosage
- Paediatric patients
6-14 years of age - 10mg tablet
- OD dosage
-Adults and adolescents ≥15 years of age AIRLUKAST may be taken
with or without food. Features Packing : Blister strips

Strawberry taste (4mg & 5mg)

Chewable tablets for kids

Once Daily dosage

Rapid onset of action Side Effects Headache

Abdominal Pain





Diarrhea Use in special populations Pregnancy :
-only if it is clearly needed

-Paediatric patients 6 months - 14 years of age.
-Paediatric patient <6 months- have not been studied.
-Use in children 2-14 years of age for seasonal allergic rhinitis
-Does not affect the growth rate of paediatric patients.

Hepatic Insufficiency :
-No dosage adjustment is required

Renal Insufficiency :
-No dosage adjustment is recommended Share with your Doctors... Pathophysiology Glenmark Generics is recalling from the US market multiple lots of Montelukast Sodium tablet(10mg), used in treatment of chronic asthma and prophylaxis, on ''off-odour'' complaints, according to US Food and Drug Administration.
Full transcript